Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Frame of Reference

Limitation of Infarct Size and the Open Artery Hypothesis

A Conversation With Eugene Braunwald, MD

Eugene Braunwald, John D. Rutherford
Download PDF
https://doi.org/10.1161/CIRCULATIONAHA.116.024714
Circulation. 2016;134:839-846
Originally published September 19, 2016
Eugene Braunwald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Rutherford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Dr Rutherford asks: How did your interest in MI begin?
    • How did your discovery of the salutary influence of carotid sinus nerve stimulation on MVo2 translate to patient care?
    • Describe this serendipitous event and its consequences
    • What were the next steps your laboratory took to investigate salvage of ischemic myocardium?
    • How did your investigations of clinical myocardial reperfusion evolve?
    • How did the TIMI Study Group start, and where did it lead?
    • What challenges remain?
    • Do you have any final reflections on your career-long pursuit of this research question?
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
Figure1

Eugene Braunwald received an MD from the New York University School of Medicine. He completed an internal medicine residency at Johns Hopkins Hospital and cardiology fellowships at Mount Sinai Hospital, Columbia University, and the National Heart Institute. He served as chief of cardiology and subsequently clinical director of the institute. From 1968 to 1972, he was the founding chair of medicine at the University of California, San Diego. From 1972 to 1996, he served as chair of medicine at the Brigham and Women’s Hospital. In 1975, he was elected to the National Academy of Sciences. He is now the Distinguished Hersey Professor of Medicine at Harvard Medical School and a senior investigator of the TIMI Study Group, which he founded in 1984.

Dr Rutherford asks: How did your interest in MI begin?

Dr Braunwald replies: I became aware of the importance of AMI in 1951 during an elective in cardiology during my senior year at the New York University School of Medicine. At the time, AMI was by far the most common cause of death in adults in the United States. Of the patients who survived to be admitted to hospitals (no one knew how many AMI patients failed to reach hospital emergency departments), about one third died before discharge, either suddenly, presumably from an arrhythmia, or secondary to pump failure. Of the patients who were discharged alive, about one quarter died within a year, most frequently as a consequence of heart failure or recurrent MI. Pathologists had taught that AMI was usually associated with coronary thrombosis. Indeed, during my cardiology elective, Herrick’s classic article describing AMI was required reading. Its title, “Clinical Features of Sudden Obstruction of the Coronary Arteries,” showed how these 2 conditions (coronary occlusion and AMI) were intertwined.1 My direct involvement in the care of several patients who did not survive the acute event left a lasting impression on me and stimulated my interest in a career in cardiovascular research, with a special emphasis on AMI.

In 1955, I began my third fellowship in cardiovascular research in the Laboratory of Cardiovascular Physiology headed by the noted physiologist Stanley J. Sarnoff at the (then) National Heart Institute (now the National Heart, Lung and Blood Institute). I participated in the design and conduct of experiments in isolated dog hearts to identify the determinants of myocardial oxygen consumption (MVo2) and of coronary blood flow.2,3 We viewed these as interesting, perhaps important, physiological studies, but we did not grasp their potential clinical implications.

In the early 1960s, advances in continuous electrocardiographic monitoring, automatic alarms for arrhythmias, and closed chest resuscitation led to the development of coronary care units, which proved to be very effective in the prevention of primary arrhythmic deaths. This notable advance reduced the hospital mortality of AMI by about half, leaving pump failure as the major cause of in-hospital mortality. Pump failure, the thinking went, was a function of the extent and severity of the imbalance between myocardial O2 supply and demand. As a consequence, the determinants of MVo2 and of coronary blood flow rapidly assumed great clinical relevance. Therefore, when I was assigned my own research laboratories in the institute in 1963, together with John Ross, Edmund Sonnenblick, and James Covell, we redoubled our efforts in studying MVo2. By 1968, we had concluded that 3 features of cardiac activity—myocardial tension development, frequency of contraction, and contractility—account for >90% of the MVo2.4,5

How did your discovery of the salutary influence of carotid sinus nerve stimulation on MVo2 translate to patient care?

In 1947, Samuel Levine and Proctor Harvey at the (then) Peter Bent Brigham Hospital observed that massaging the carotid sinus could relieve episodes of angina pectoris. In the late 1960s, the management of angina pectoris consisted primarily of sublingual nitroglycerin and oral β-blockers. On the basis of Levine and Harvey’s observations, we hypothesized that an additional, perhaps more potent approach to restoration of the balance between myocardial O2 supply and demand might be achieved by implanting a transcutaneous carotid sinus nerve stimulator, which could be activated externally by the patient at times of need. In 1967, my first wife, Nina Braunwald,* Steven Epstein, and I accomplished this, and we observed that carotid sinus nerve stimulation was indeed successful both in relieving severe angina and, when used prophylactically, in preventing exertion-induced ischemia.6 While we were conducting additional clinical studies with the device to obtain regulatory approval, Rene Favaloro at The Cleveland Clinic successfully performed cardiac revascularization using a coronary vein graft to bypass an occluded right coronary artery. Enhancing myocardial O2 supply by this direct approach proved much more effective in preventing myocardial ischemia than carotid sinus nerve stimulation. Therefore, we discontinued our efforts with the latter, but not before I experienced a serendipitous event that would have a profound effect on my subsequent professional life.

Describe this serendipitous event and its consequences

In early 1968, one of our patients with the carotid sinus nerve stimulation system in place was admitted to the National Heart, Lung and Blood Institute during the early hours of a STEMI. His ECG was recorded when the stimulator was in both the on and off modes on several occasions. Subsequent review showed that the extensive ST-segment elevations in the absence of stimulation were markedly reduced during activation. I was surprised by this observation because I (and others at the time) had thought of thrombotic coronary occlusion and subsequent MI as sudden events, as had been reflected in the title of Herrick’s article.1 However, the observations in this patient suggested that in the early hours of an AMI, a reduction of myocardial O2 demands, as occurred with carotid sinus nerve stimulation, might actually reduce what had, until then, been considered to be sudden, irreversible ischemic myocardial damage. If so, it might be possible in patients with AMI to protect some of the ischemic but still viable myocardium by quickly restoring the balance between myocardial O2 supply and demand.

What were the next steps your laboratory took to investigate salvage of ischemic myocardium?

After moving to the University of California, San Diego in 1968 with several colleagues from the National Institutes of Health, and joined by a talented postdoctoral fellow, the late Peter Maroko, we returned to the dog TIMI laboratory to test the hypothesis that the severity of ischemia and hence of ischemic damage produced by coronary occlusion could be reduced by altering the imbalance between myocardial O2 supply and demand.7,8 We related acute ischemia by correlating epicardial ST-segment alterations with myocardial necrosis by measuring myocardial creatine phosphokinaseconcentrations, a marker of myocardial viability, and by histology in the heart excised 24 hours after the intervention. We observed that increased myocardial O2 supply by reperfusion of the ischemic zone as late as 3 hours after coronary occlusion could salvage jeopardized myocardium9 (Figure 1). In the presence of coronary occlusion, tachycardia induced by electric stimulation and β-adrenergic stimulation with isoproterenol, both of which augment MVo2, increased ischemic damage. In contrast, intravenous propranolol, a β-blocker that reduced MVo2, also reduced the extent of myocardial necrosis. From these studies, we proposed that severely ischemic myocardium destined to become necrotic could be salvaged by opening the IRA (hence the open artery hypothesis) but also by reducing MVo2. We concluded the article as follows:

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Comparison between the relationships between ST-segment elevation 15 minutes after occlusion and creatine phosphokinase (CPK) activity 24 hours later at the same myocardial sites. Bottom (solid) line indicates the control group; middle (dotted) line, after administration of a combination of glucose-insulin-potassium and propranolol starting 3 hours after occlusion; and top (dashed) line, reperfusion of coronary arteries 3 hours after occlusion. The slope of the lower line is statistically different from the slope of the other lines, showing lesser CPK depression resulting from glucose-insulin-potassium and propranolol administration or reperfusion at 3 hours after occlusion than in the control group. Experiments in 198 sites on 26 dogs. Reprinted with permission from Maroko PR, Braunwald E. Modification of myocardial infarction size after coronary occlusion. Ann Intern Med. 1973;79:720–733.9 http://annals.org/article.aspx?articleid=688077. Copyright © 1973, American College of Physicians.

Of critical interest, from the clinical point of view, is the finding that the severity and extent of myocardial ischemic injury resulting from coronary occlusion could be radically altered not only by pretreatment of the animal but also by an appropriate intervention as late as 3 hours after the coronary occlusion. This suggests that measures designed for reduction of myocardial oxygen demands and improvement of coronary perfusion, when effected promptly after a patient has been brought to a hospital, might potentially reduce the ultimate size of the infarction.8

How did your investigations of clinical myocardial reperfusion evolve?

We were excited by these observations in open chest, anesthetized dogs and were anxious to extend them to patients undergoing AMI in the hope of limiting infarct size. Although the most effective intervention in our experiments had been myocardial reperfusion, in 1971, there was no practical way to reperfuse ischemic myocardium safely and rapidly during an evolving infarction. However, the picture changed dramatically in 1975 with the demonstration by Chazov and colleagues10 in a patient experiencing an STEMI that reperfusion could be accomplished by infusing streptokinase directly into the occluded IRA. After we moved to Boston and began treating patients with STEMI with this approach, it became critically important to test the hypothesis that opening the occluded IRA actually limited infarct size. Therefore, in 1981, John Markis, William Grossman, and I studied patients with STEMI who had just undergone thrombolytic reperfusion. We injected thallium-201 into the IRA that had been opened with intracoronary streptokinase. The uptake of thallium, as observed on scintigraphy, required myocardial viability. We found that the jeopardized myocardium that initially displayed no uptake of thallium-201 had in fact been salvaged by the reperfusion.11 We considered this to be the evidence in patients that we had been after since 1968, when we first considered that infarct size might be limited in patients by opening an occluded IRA, and believed that it strengthened the open artery hypothesis. However, in the early 1980s, this hypothesis was not yet widely accepted, nor was the critical importance of infarct size to ventricular function and patient survival widely appreciated. Perhaps this was due to the finding that contractile dysfunction in severely ischemic myocardium was not perceived immediately to be reversed on opening of the IRA. In 1982, Robert Kloner and I called this “prolonged, postischemic ventricular dysfunction” and “myocardial stunning.”12 We proposed that “when the myocardium is frequently stunned it may exhibit chronic postischemic left ventricular dysfunction,”12 which could be responsible for some cases of ischemic cardiomyopathy that could be reversed by reperfusion.13

In a rat model of STEMI, developed by Janice and Marc Pfeffer and Bob Kloner, we demonstrated the inverse relation between infarct size and left ventricular ejection fraction14,15 (Figure 2). The Pfeffers extended this observation by showing that the mortality of rats 1 year after infarction varied directly with infarct size.16 We then turned our full attention to clinical efforts to reduce infarct size.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Scatterplot showing relationship between ejection fraction index and histologically determined myocardial infarct size in rats with healed myocardial infarction (n=104; P<0.001). Reprinted from Pfeffer and Braunwald.15

How did the TIMI Study Group start, and where did it lead?

In 1984, I was invited by the National Heart, Lung and Blood Institute to chair a clinical trials group, the TIMI Study Group, to optimize thrombolytic therapy. This was an exciting time in the field. Schröder et al17 had just shown that thrombolysis could be achieved by the rapid intravenous injection of large doses of streptokinase, enhancing the likelihood that myocardial reperfusion could be accomplished relatively easily in almost any hospital emergency room. As TIMI began its first study, the first 2 mega-trials of streptokinase in AMI, the GISSI18 and ISIS 219 trials, were underway but had not been completed. In the first TIMI trial, we compared the efficacy and safety of the intravenous administration of 2 thrombolytic drugs (streptokinase and tissue-type plasminogen activator, one of the first agents produced by the applications of recombinant biology to drug development) in patients with STEMI. The trial was halted early by the Data Safety Monitoring Board because of the clear superiority of tissue-type plasminogen activator in achieving full reperfusion, which we referred to as TIMI 3 flow.20 In patients in whom the IRA had been opened, regardless of which thrombolytic agent was used, left ventricular function measured a week later was improved.21 Moreover, mortality at 1 year was ≈40% lower in patients who had an open compared with an occluded IRA 90 minutes after randomization,22 providing further support for the open artery hypothesis.

From the TIMI 2 trial, we learned that early intravenous injection of a β-blocker reduced the risk of reinfarction and recurrent ischemia,23 a finding consistent with the cardioprotective action of β-blockade observed in our dog experiments 2 decades earlier.7,8 However, the trial was underpowered to examine the effects on mortality. The results of the TIMI 3 trial on patients with non–ST-segment–elevation acute coronary syndromes came as something of a surprise. On arteriography, we observed coronary obstruction consistently but clear evidence of thrombus in only about one third of these patients.24 Tissue-type plasminogen activator had no clinical benefit; it actually was found to be associated with numeric increases in intracranial hemorrhage, death, or AMI. However, we did observe that an invasive approach with balloon angioplasty to open the IRA (it was before the introduction of stents) resulted in a reduction in rehospitalization for recurrent severe myocardial ischemia.25 It was not until we carried out TACTICS-TIMI 18 in 2001 that we observed clearly that an invasive strategy with early coronary arteriography followed by reperfusion resulted in improved clinical outcomes in patients with non–ST-segment–elevation acute coronary syndromes.26 So, although achieving reperfusion by thrombolysis was not helpful in such patients, the clinical benefits derived from mechanical myocardial reperfusion were certainly consistent with the open artery hypothesis.

The most authoritative validation of the hypothesis came from the GUSTO investigators, who studied 2431 patients with STEMI by coronary arteriography and stated the following in 1993:

...the hypothesis that more rapid restoration of flow through the IRA after the initiation of thrombolytic therapy may better preserve left ventricular function and improve survival among patients with AMI has been controversial...This study [the GUSTO trial and its angiographic substudy] suggests...that more rapid and complete restoration of coronary flow through the IRA results in improved ventricular performance and lower mortality among patients with AMI.27

As techniques for achieving reperfusion of jeopardized myocardium improved progressively, from streptokinase to tissue-type plasminogen activator, to tenecteplase,28 to balloon angioplasty, to bare metal and several generations of drug-eluting stents, combined with an anticoagulant and dual antiplatelet therapy,29 and as operator experience accumulated, there has been steady improvement in clinical outcomes in patients with STEMI. In our dog experiments in 1971, we suggested that the timing of myocardial reperfusion is important.8,9 This concept was subsequently quantified by the important experiments by Reimer et al.30 Enormous efforts worldwide were made to shorten the interval between the onset of symptoms of AMI and reperfusion. Hence, the credo for the treatment of STEMI has become “Open the IRA, and open it just as quickly as possible.” Although PCI is certainly superior to thrombolysis, when rapid PCI is not available or feasible, the vessel may be opened with a thrombolytic, begun as soon as possible, followed by PCI. This approach has been referred to as pharmacoinvasive therapy.31

What challenges remain?

Despite the salutary results of contemporary therapy for STEMI, several problems still require attention. The first is myocardial reperfusion injury. In 1985, Kloner and I called attention to the fact that reperfusion of jeopardized myocardium is a double-edged sword resulting simultaneously in myocardial salvage but also accelerated injury.32 Three decades later, prevention of the latter effect remains a challenge.33

The second is the late open artery hypothesis. The benefit of late opening of the IRA, that is, when it can no longer be expected to salvage acutely ischemic, jeopardized myocardium, is sometimes referred to as the late infarct artery hypothesis. Late reperfusion of infarcts has been shown in rats, pigs, and dogs to produce thicker infarct scars and to limit, often even prevent, post-AMI infarct expansion.34,35 We and others have suggested that late patency of the IRA permits additional collateral blood flow to the peri-infarct zone, may provide a “scaffold” that supports the surrounding myocardium, and may increase electric stability.36–38 It has been observed that post-AMI patients with occluded IRAs may exhibit progressive ventricular dilatation, whereas patients with similar ventricular volumes but patent IRAs do not.39 Although there are strong suggestive findings for these and other potential benefits of late reperfusion, rigorous evidence to support the clinical benefit of a late open artery is not available.

To address this question, the OAT, an National Institutes of Health–supported trial led by Hochman, enrolled patients with persistent total occlusion of the IRAs 3 to 28 days after AMI. All received optimal medical therapy; one half were randomized to PCI with stenting. Randomization to PCI did not reduce the primary end point (death, reinfarction, or heart failure.)40 In an angiographic substudy, long-term (1 year) patency was present in 83% of the patients randomized to PCI compared with 25% of those initially assigned to medical therapy. The authors concluded that, on the basis of their angiographic findings “and the lack of clinical benefit over an average of 3 years follow-up, routine PCI is not recommended for persistent IRA occlusion in stable coronary artery disease.”41

I agree with this conclusion of this well-conducted trial and its angiographic substudy. However, it must be appreciated that OAT tested a therapy (PCI) but did not test the late open artery hypothesis directly. Indeed, in the angiographic substudy, the investigators reported that “regardless of initial treatment assignments, patients with a patent IRA at follow-uphad a greater increase in left ventricular ejection fraction than those with an occluded artery (absolute difference of 3.0%; P=0.003).”41 This observation actually supports the hypothesis. Subsequently, the authors of a meta-analysis of 5 trials of late PCI for totally occluded IRAs (including the above-mentioned substudy41) concluded that “a statistically significant improvement in cardiac function and a reduction in adverse remodeling...supports [sic] the pathophysiologic value of the open-artery hypothesis.”42

Operator experience, equipment, and concomitant antithrombotic treatment to support percutaneous opening of totally occluded coronary arteries have all improved substantially in the 13 years since patients entered the OAT trial.43 I believe that we have not heard the last word about the late open artery hypothesis.

After decades of preclinical research, after hundreds of thousands of patients with AMI have participated in clinical trials of various therapies, and after many hundreds of articles on the subject of the treatment of AMI have been published, the question “Does infarct size matter?” was recently posed again.44 With all that we have learned about AMI and the many factors that influence outcome, do measurements of infarct size still provide information of clinical importance? Yes, infarct size still matters. In a recent analysis by Stone et al45 of 2632 patients with AMI in 10 trials, infarct size measured within 30 days after early PCI remained a significant determinant of clinical outcome after hospital discharge. There is obvious room for improvement of post-AMI outcomes, and one approach could be early intravenous β-blockade, which I consider the third challenge.

As already indicated, our results with this intervention were encouraging both in the dog model7,8 and in patients in the TIMI 2 trial.23 Our work and that of others, including the excellent work of Reimer et al,46 have indicated that the limitation of infarct size by β-blockade is time dependent (just as it is for myocardial reperfusion). Early intravenous administration should not be confused with long-term oral β-blockade begun after the infarction is complete. The latter has been shown repeatedly to reduce subsequent mortality and recurrent infarction, and oral β-blockade has become a cornerstone of post-AMI therapy. Until recently, despite a large number of trials, the jury has still been out on the benefit of early intravenous β-blockade,47 perhaps because of the varying definitions of early used by different investigators.

This important issue has recently been readdressed in a series of rigorous studies by Ibanez and associates,48 first in a pig model of STEMI and then in a double-blind trial of patients with anterior wall STEMI. Intravenous metoprolol or placebo was administered before reperfusion. Magnetic resonance imaging performed at 1 week and repeated at 6 months showed reduced IS, higher left ventricular ejection fraction, and reduced admissions for heart failure.49 These and related studies using esmolol, the ultra– short-acting β-blocker,50 have revived our suggestion that early intravenous β-blockade in suitable patients with AMI can limit infarct size and provide clinical benefit.51 This rejuvenated hypothesis should now be tested in a large trial on clinical outcomes in patients with STEMI treated with early PCI, examining patients with large, anterior wall infarcts with adequate doses of a β-blocker administered at least 15 minutes before reperfusion.

Do you have any final reflections on your career-long pursuit of this research question?

Looking back, “Limitation of Infarct Size and the Open Artery Hypothesis” has been the most gratifying of my adventures in cardiovascular research.52 This short history suggests that we simply moved from one victory to another. It has, in fact, not always been a smooth ride. There have been some bumps in the road, with a few false starts, blind alleys, errors (some on my part), missed opportunities, and plenty of sniping from competitors, but all of this is fairly typical of clinical science in a rapidly changing field with high stakes.

I have had 3 strokes of good fortune in my professional life. The first is that as a trainee I was stimulated to work in cardiovascular science at a time when this field was about to enter its golden period, during which the opportunities in translational research were immense. The second is that I landed in the right place at the right time. The National Heart, Lung and Blood Institute, University of California, San Diego, and Harvard/Brigham each provided me with the intellectual and clinical environments required for the type of research that our group conducted. The leaders of these institutions gave me the time and opportunity to conduct research even though my “day jobs” were largely administrative. The third and perhaps most important stroke of fortune has been the opportunity to work with dozens of brilliant, enthusiastic, and dedicated colleagues and trainees on this research, who deserve great credit for what has been accomplished. They are too numerous to mention, but in particular, this work would not have been possible without the stimulation of my mentor, Stanley J. Sarnoff, and the contributions of Peter R. Maroko*, Robert A. Kloner, James E. Muller, Marc A. Pfeffer, John Ross, Jr, Burton E. Sobel*, Edmund H. Sonnenblick*, and in the past 3 decades, of course, my colleagues in the TIMI Group.

Disclosures

None.

Footnotes

  • Inquiries related to this profile, or the “Paths to Discovery” series, may be directed to the Editorial Office at circ{at}circulationjournal.org.

  • Circulation is available at http://circ.ahajournals.org.

  • ↵* Deceased.

  • Abbreviations Used in This Article
    AMI
    acute myocardial infarction
    GISSI
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico
    GUSTO
    Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
    IRA
    infarct-related artery
    ISIS 2
    Second International Study of Infarct Survival
    MI
    myocardial infarction
    OAT
    Occluded Artery Trial
    PCI
    percutaneous coronary intervention
    STEMI
    ST-elevation myocardial infarction
    TACTICS
    Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy
    TIMI
    Thrombolysis in Myocardial Infarction

  • © 2016 American Heart Association, Inc.

References

  1. 1.↵
    1. Herrick JB
    . Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912;9:2015–2022.
    OpenUrl
  2. 2.↵
    1. Sarnoff SJ,
    2. Braunwald E,
    3. Welch GH Jr.,
    4. Case RB,
    5. Stainsby WN,
    6. Macruz R
    . Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol. 1958;192:148–156.
    OpenUrl
  3. 3.↵
    1. Braunwald E,
    2. Sarnoff SJ,
    3. Case RB,
    4. Stainsby WN,
    5. Welch GH Jr.
    . Hemodynamic determinants of coronary flow: effect of changes in aortic pressure and cardiac output on the relationship between myocardial oxygen consumption and coronary flow. Am J Physiol. 1958;192:157–163.
    OpenUrl
  4. 4.↵
    1. Braunwald E
    . Thirteenth Bowditch Lecture: the determinants of myocardial oxygen consumption. Physiologist. 1969;12:65–93.
    OpenUrlPubMed
  5. 5.↵
    1. Braunwald E
    . Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol. 1971;27:416–432.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Braunwald E,
    2. Epstein SE,
    3. Glick G,
    4. Wechsler AS,
    5. Braunwald NS
    . Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Engl J Med. 1967;277:1278–1283. doi: 10.1056/NEJM196712142772402.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Braunwald E,
    2. Covell JW,
    3. Maroko PR,
    4. Ross J Jr.
    . Effects of drugs and of counterpulsation on myocardial oxygen consumption. Circulation. 1969;40(suppl IV):220–228.
    OpenUrl
  8. 8.↵
    1. Maroko PR,
    2. Kjekshus JK,
    3. Sobel BE,
    4. Watanabe T,
    5. Covell JW,
    6. Ross J Jr.,
    7. Braunwald E
    . Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67–82.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Maroko PR,
    2. Braunwald E
    . Modification of myocardial infarction size after coronary occlusion. Ann Intern Med. 1973;79:720–733.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Chazov EI,
    2. Matveeva LS,
    3. Mazaev AV,
    4. Sargin KE,
    5. Sadovskaia GV,
    6. Ruda MI
    . Intracoronary administration of fibrinolysin in acute myocardial infarct [in Russian]. Ter Arkh. 1976;48:8–19.
    OpenUrlPubMed
  11. 11.↵
    1. Markis JE,
    2. Malagold M,
    3. Parker JA,
    4. Silverman KJ,
    5. Barry WH,
    6. Als AV,
    7. Paulin S,
    8. Grossman W,
    9. Braunwald E
    . Myocardial salvage after intracoronary thrombolysis with streptokinase in acute myocardial infarction. N Engl J Med. 1981;305:777–782. doi: 10.1056/NEJM198110013051401.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Braunwald E,
    2. Kloner RA
    . The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Braunwald E,
    2. Rutherford JD
    . Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium.” J Am Coll Cardiol. 1986;8:1467–1470.
    OpenUrlFREE Full Text
  14. 14.↵
    1. Pfeffer MA,
    2. Pfeffer JM,
    3. Fishbein MC,
    4. Fletcher PJ,
    5. Spadaro J,
    6. Kloner RA,
    7. Braunwald E
    . Myocardial infarct size and ventricular function in rats. Circ Res. 1979;44:503–512.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Pfeffer MA,
    2. Braunwald E
    . Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–1172.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Pfeffer MA,
    2. Pfeffer JM
    . Ventricular enlargement and reduced survival after myocardial infarction. Circulation 1987;75(suppl IV):IV93–IV97.
    OpenUrlPubMed
  17. 17.↵
    1. Schröder R,
    2. Biamino G,
    3. von Leitner ER,
    4. Linderer T,
    5. Brüggemann T,
    6. Heitz J,
    7. Vöhringer HF,
    8. Wegscheider K
    . Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 1983;67:536–548.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397–402.
    OpenUrlCrossRefPubMed
  19. 19.↵
    ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;1:349–360.
    OpenUrl
  20. 20.↵
    TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932–936.
    OpenUrlPubMed
  21. 21.↵
    1. Sheehan FH,
    2. Braunwald E,
    3. Canner P,
    4. Dodge HT,
    5. Gore J,
    6. Van Natta P,
    7. Passamani ER,
    8. Williams DO,
    9. Zaret B
    . The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) trial. Circulation. 1987;75:817–829.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Dalen JE,
    2. Gore JM,
    3. Braunwald E,
    4. Borer J,
    5. Goldberg RJ,
    6. Passamani ER,
    7. Forman S,
    8. Knatterud G
    . Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol. 1988;62:179–185.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Roberts R,
    2. Rogers WJ,
    3. Mueller HS,
    4. Lambrew CT,
    5. Diver DJ,
    6. Smith HC,
    7. Willerson JT,
    8. Knatterud GL,
    9. Forman S,
    10. Passamani E,
    11. Zaret BL,
    12. Wackers FJT,
    13. Braunwald E
    . Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422–437.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Circulation 1993;87:38–52.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI III B Trial: Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545–1556.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Cannon CP,
    2. Weintraub WS,
    3. Demopoulos LA,
    4. Vicari R,
    5. Frey MJ,
    6. Lakkis N,
    7. Neumann FJ,
    8. Robertson DH,
    9. DeLucca PT,
    10. DiBattiste PM,
    11. Gibson CM,
    12. Braunwald E
    ; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)–Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887. doi: 10.1056/NEJM200106213442501.
    OpenUrlCrossRefPubMed
  27. 27.↵
    GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Cannon CP,
    2. Gibson CM,
    3. McCabe CH,
    4. Adgey AA,
    5. Schweiger MJ,
    6. Sequeira RF,
    7. Grollier G,
    8. Giugliano RP,
    9. Frey M,
    10. Mueller HS,
    11. Steingart RM,
    12. Weaver WD,
    13. Van de Werf F,
    14. Braunwald E
    . TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98:2805–2814.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Sabatine MS,
    2. Cannon CP,
    3. Gibson CM,
    4. López-Sendón JL,
    5. Montalescot G,
    6. Theroux P,
    7. Claeys MJ,
    8. Cools F,
    9. Hill KA,
    10. Skene AM,
    11. McCabe CH,
    12. Braunwald E
    ; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189. doi: 10.1056/NEJMoa050522.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Reimer KA,
    2. Lowe JE,
    3. Rasmussen MM,
    4. Jennings RB
    . The wavefront phenomenon of ischemic cell death, 1: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786–794.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Dauerman HL,
    2. Sobel BE
    1. Antman EA,
    2. Braunwald E
    : Pharmacologic developments likely to enhance the benefits of pharmacoinvasive therapy. Dauerman HL, Sobel BE, . In Pharmacoinvasive Therapy in Acute Myocardial Infarction. New York, NY: Marcel Dekker; 2005.
  32. 32.↵
    1. Braunwald E,
    2. Kloner RA
    . Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713–1719. doi: 10.1172/JCI112160.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Hausenloy DJ,
    2. Botker HE,
    3. Engstrom T,
    4. Erlinge D,
    5. Heusch G,
    6. Ibanez B,
    7. Kloner RA,
    8. Ovize M,
    9. Yellon DM,
    10. Garcia-Dorado D
    . Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations [published online ahead of print April 26, 2016]. Eur Heart J. doi: http://dx.doi.org/10.1093/eurheartj/ehw145. http://eurheartj.oxfordjournals.org/content/early/2016/04/25/eurheartj.ehw145.long. Accessed September 1, 2016.
  34. 34.↵
    1. Hochman JS,
    2. Choo H
    . Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987;75:299–306.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Nakagawa M,
    2. Takemura G,
    3. Kanamori H,
    4. Goto K,
    5. Maruyama R,
    6. Tsujimoto A,
    7. Ohno T,
    8. Okada H,
    9. Ogino A,
    10. Esaki M,
    11. Miyata S,
    12. Li L,
    13. Ushikoshi H,
    14. Aoyama T,
    15. Kawasaki M,
    16. Nagashima K,
    17. Fujiwara T,
    18. Minatoguchi S,
    19. Fujiwara H
    . Mechanisms by which late coronary reperfusion mitigates postinfarction cardiac remodeling. Circ Res. 2008;103:98–106. doi: 10.1161/CIRCRESAHA.108.177568.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Braunwald E
    . Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation. 1989;79:441–444.
    OpenUrlFREE Full Text
  37. 37.↵
    1. Gersh BJ
    . Benefits of the open artery: beyond myocardial salvage. J Myocard Ischemia. 1990;2:15–37.
    OpenUrl
  38. 38.↵
    1. Kim CB,
    2. Braunwald E
    . Potential benefits of late reperfusion of infarcted myocardium: the open artery hypothesis. Circulation. 1993;88(pt 1):2426–2436.
    OpenUrlFREE Full Text
  39. 39.↵
    1. Erlebacher JA,
    2. Weiss JL,
    3. Eaton LW,
    4. Kallman C,
    5. Weisfeldt ML,
    6. Bulkley BH
    . Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 1982;49:1120–1126.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Hochman JS,
    2. Lamas GA,
    3. Buller CE,
    4. Dzavik V,
    5. Reynolds HR,
    6. Abramsky SJ,
    7. Forman S,
    8. Ruzyllo W,
    9. Maggioni AP,
    10. White H,
    11. Sadowski Z,
    12. Carvalho AC,
    13. Rankin JM,
    14. Renkin JP,
    15. Steg PG,
    16. Mascette AM,
    17. Sopko G,
    18. Pfisterer ME,
    19. Leor J,
    20. Fridrich V,
    21. Mark DB,
    22. Knatterud GL
    ; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–2407. doi: 10.1056/NEJMoa066139.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Dzavík V,
    2. Buller CE,
    3. Lamas GA,
    4. Rankin JM,
    5. Mancini GB,
    6. Cantor WJ,
    7. Carere RJ,
    8. Ross JR,
    9. Atchison D,
    10. Forman S,
    11. Thomas B,
    12. Buszman P,
    13. Vozzi C,
    14. Glanz A,
    15. Cohen EA,
    16. Meciar P,
    17. Devlin G,
    18. Mascette A,
    19. Sopko G,
    20. Knatterud GL,
    21. Hochman JS
    ; TOSCA-2 Investigators. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation. 2006;114:2449–2457. doi: 10.1161/CIRCULATIONAHA.106.669432.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Appleton DL,
    2. Abbate A,
    3. Biondi-Zoccai GG
    . Late percutaneous coronary intervention for the totally occluded infarct-related artery: a meta-analysis of the effects on cardiac function and remodeling. Catheter Cardiovasc Interv. 2008;71:772–781. doi: 10.1002/ccd.21468.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Galassi AR,
    2. Brilakis ES,
    3. Boukhris M,
    4. Tomasello SD,
    5. Sianos G,
    6. Karmpaliotis D,
    7. Di Mario C,
    8. Strauss BH,
    9. Rinfret S,
    10. Yamane M,
    11. Katoh O,
    12. Werner GS,
    13. Reifart N
    . Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview [published online ahead of print August 7, 2015]. Eur Heart J. doi: http://dx.doi.org/10.1093/eurheartj/ehv391. http://eurheartj.oxfordjournals.org/content/early/2015/08/06/eurheartj.ehv391.long. Accessed September 1, 2016.
  44. 44.↵
    1. Gibbons RJ,
    2. Araoz P
    . Does infarct size matter? J Am Coll Cardiol. 2016;67:1684–1686. doi: 10.1016/j.jacc.2016.02.022.
    OpenUrlFREE Full Text
  45. 45.↵
    1. Stone GW,
    2. Selker HP,
    3. Thiele H,
    4. Patel MR,
    5. Udelson JE,
    6. Ohman EM,
    7. Maehara A,
    8. Eitel I,
    9. Granger CB,
    10. Jenkins PL,
    11. Nichols M,
    12. Ben-Yehuda O
    . Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol. 2016;67:1674–1683. doi: 10.1016/j.jacc.2016.01.069.
    OpenUrlFREE Full Text
  46. 46.↵
    1. Reimer KA,
    2. Rasmussen MM,
    3. Jennings RB
    . Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res. 1973;33:353–363.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Bates ER
    . Role of intravenous beta-blockers in the treatment of ST-elevation myocardial infarction: of mice (dogs, pigs) and men. Circulation. 2007;115:2904–2906. doi: 10.1161/CIRCULATIONAHA.107.707968.
    OpenUrlFREE Full Text
  48. 48.↵
    1. Ibanez B,
    2. Macaya C,
    3. Sánchez-Brunete V,
    4. Pizarro G,
    5. Fernández-Friera L,
    6. Mateos A,
    7. Fernández-Ortiz A,
    8. García-Ruiz JM,
    9. García-Álvarez A,
    10. Iñiguez A,
    11. Jiménez-Borreguero J,
    12. López-Romero P,
    13. Fernández-Jiménez R,
    14. Goicolea J,
    15. Ruiz-Mateos B,
    16. Bastante T,
    17. Arias M,
    18. Iglesias-Vázquez JA,
    19. Rodriguez MD,
    20. Escalera N,
    21. Acebal C,
    22. Cabrera JA,
    23. Valenciano J,
    24. Pérez de Prado A,
    25. Fernández-Campos MJ,
    26. Casado I,
    27. García-Rubira JC,
    28. García-Prieto J,
    29. Sanz-Rosa D,
    30. Cuellas C,
    31. Hernández-Antolín R,
    32. Albarrán A,
    33. Fernández-Vázquez F,
    34. de la Torre-Hernández JM,
    35. Pocock S,
    36. Sanz G,
    37. Fuster V
    . Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation. 2013;128:1495–1503. doi: 10.1161/CIRCULATIONAHA.113.003653.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Pizarro G,
    2. Fernández-Friera L,
    3. Fuster V,
    4. Fernández-Jiménez R,
    5. García-Ruiz JM,
    6. García-Álvarez A,
    7. Mateos A,
    8. Barreiro MV,
    9. Escalera N,
    10. Rodriguez MD,
    11. de Miguel A,
    12. García-Lunar I,
    13. Parra-Fuertes JJ,
    14. Sánchez-González J,
    15. Pardillos L,
    16. Nieto B,
    17. Jiménez A,
    18. Abejón R,
    19. Bastante T,
    20. Martínez de Vega V,
    21. Cabrera JA,
    22. López-Melgar B,
    23. Guzman G,
    24. García-Prieto J,
    25. Mirelis JG,
    26. Zamorano JL,
    27. Albarrán A,
    28. Goicolea J,
    29. Escaned J,
    30. Pocock S,
    31. Iñiguez A,
    32. Fernández-Ortiz A,
    33. Sánchez-Brunete V,
    34. Macaya C,
    35. Ibanez B
    . Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol. 2014;63:2356–2362. doi: 10.1016/j.jacc.2014.03.014.
    OpenUrlFREE Full Text
  50. 50.↵
    1. Er F,
    2. Dahlem KM,
    3. Nia AM,
    4. Erdmann E,
    5. Waltenberger J,
    6. Hellmich M,
    7. Kuhr K,
    8. Le MT,
    9. Herrfurth T,
    10. Taghiyev Z,
    11. Biesenbach E,
    12. Yüksel D,
    13. Eran-Ergöknil A,
    14. Vanezi M,
    15. Caglayan E,
    16. Gassanov N
    . Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction: the BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial. JACC Cardiovasc Interv. 2016;9:231–240. doi: 10.1016/j.jcin.2015.10.035.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Kloner RA,
    2. Braunwald E
    . Intravenous beta-blockade for limiting myocardial infarct size: Rejuvenation of a concept. J Am Coll Cardiol. 2016;67:2105–2107. doi: 10.1016/j.jacc.2016.02.061.
    OpenUrlFREE Full Text
  52. 52.↵
    1. Braunwald E
    . Adventures in cardiovascular research. Circulation. 2009;120:170–180. doi: 10.1161/CIRCULATIONAHA.109.860965.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
September 20, 2016, Volume 134, Issue 12
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Dr Rutherford asks: How did your interest in MI begin?
    • How did your discovery of the salutary influence of carotid sinus nerve stimulation on MVo2 translate to patient care?
    • Describe this serendipitous event and its consequences
    • What were the next steps your laboratory took to investigate salvage of ischemic myocardium?
    • How did your investigations of clinical myocardial reperfusion evolve?
    • How did the TIMI Study Group start, and where did it lead?
    • What challenges remain?
    • Do you have any final reflections on your career-long pursuit of this research question?
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Limitation of Infarct Size and the Open Artery Hypothesis
    Eugene Braunwald and John D. Rutherford
    Circulation. 2016;134:839-846, originally published September 19, 2016
    https://doi.org/10.1161/CIRCULATIONAHA.116.024714

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Limitation of Infarct Size and the Open Artery Hypothesis
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Limitation of Infarct Size and the Open Artery Hypothesis
    Eugene Braunwald and John D. Rutherford
    Circulation. 2016;134:839-846, originally published September 19, 2016
    https://doi.org/10.1161/CIRCULATIONAHA.116.024714
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured